Gabriele Niedermann
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming.
Journal: Signal transduction and targeted therapy
Published: February 13, 2026
CD4+ T cells facilitate the RT-induced abscopal effect by promoting antigen cross-presentation to CD8+ T cells at unirradiated tumor sites.
Journal: Journal for immunotherapy of cancer
Published: January 22, 2026
Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.
Journal: International journal of cancer
Published: October 20, 2025
Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature review.
Journal: Clinical and translational radiation oncology
Published: June 25, 2025
SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis.
Journal: Nature communications
Published: February 06, 2025
A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: November 11, 2024
Author Correction: Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice.
Journal: Nature communications
Published: August 05, 2024
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
Journal: Theranostics
Published: December 14, 2023
A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
Journal: Research square
Published: November 28, 2023
Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma.
Journal: Journal of cancer research and clinical oncology
Published: November 13, 2023
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Journal: Signal transduction and targeted therapy
Published: October 11, 2023
Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: September 07, 2023
Last Updated: 09/26/2026